Cwmgarw Consulting Group LLC launches to create value for client companies by developing innovative registration strategies coupled with expedient worldwide regulatory execution

(PRLEAP.COM) Cwmgarw Consulting Group LLC, a new privately held company bringing critical perspective to development strategy in the pharmaceutical / biotechnology industry, has launched (www.cwmgarw.net). The company adopts a worldwide approach to registration strategy coupled with expedient execution — focusing on value creation for its clients.

Development of products in the pharmaceutical/biotechnology industry takes 12-15 years and costs about $800M. “Development times and substantial costs are becoming untenable,” says Dr. Richard N. Williams, the founder of Cwmgarw Consulting Group, “clearly, new paradigms are required to overhaul a system that is struggling.” Through experience gained in large Pharma and emerging companies, Cwmgarw offers innovative strategies for product registration and licensing optimization. As stated by Williams, “the challenge is to merge business goals with solid development science to create value in the shortest possible timeframe. And, of course, a solid development and registration plan also optimizes licensing opportunities.”

Emerging biotechnology companies are now looking through an IPO window that does not guarantee sufficient funds relative to the cost of capital. And large Pharma firms are actively pursuing strategic initiatives to slash time off their development processes. Cwmgarw Consulting Group provides innovative solutions for these challenges by focusing on development strategies that save time, maintain quality, and utilize contemporary flexible approaches based upon successful hands-on experience.

PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy